Introduction
Fibroblast growth factor 2 (FGF-2 or basic FGF) belongs to a large family of structurally related multifunctional growth factors. The FGF signaling pathway has been shown to play determinant roles not only in development and physiopathological processes but also in tumorigenesis and tumor progression (see, for review, Okada-Ban et al., 2000; Powers et al., 2000) FGF-2 is translated from a single gene into several isoforms. In addition to the common 18 kDa cytoplasmic isoform, four high molecular weight isoforms characterized by the presence of a nuclear localization sequence can be alternatively synthesized (Bugler et al., 1991; Arnaud et al., 1999) . Several recent studies have associated nuclear FGF-2 expression with poor prognosis in human cancer: astrocytic tumors (Fukui et al., 2003) , thyroid cancer along with subsequent metastasis (Boelaert et al., 2003) and increased recurrence of pituitary tumors (Fukui et al., 2002) . It has also been demonstrated that some biological activities of FGF-2 depend on an intracrine mode of action and suggest that the high molecular weight FGF-2 could trigger putative nuclear target(s) (Delrieu, 2000) . However, these targets have not yet been characterized. Using the two-hybrid screening system to search for proteins that interact with FGF-2, a putatively antiapoptotic 55 kDa nuclear factor, FIF (FGF-2-interacting factor), was identified. Interestingly, this factor only interacts with FGF-2 and not with the other FGFs tested so far ( Van den Berghe et al., 2000) . The highest molecular weight 34 kDa nuclear FGF-2 isoform has been postulated to be involved in cell survival (Arnaud et al., 1999) .
The Tet-Off system of conditional switching of a specific gene represents a unique and powerful tool to regulate expression both in vitro and in vivo (Gossen and Bujard, 1992) . The roles of the high molecular weight FGF-2 isoforms were investigated by conditional expression. Results show that only the high molecular weight FGF-2 expression allowed the growth of NIH-3T3 cells in low serum-containing medium (Gualandris et al., 1999) . More recently, using conditional expression of FGF-2 in HEC-1B adenocarcinoma cells, it was reported that FGF-2 expression significantly affects the initial tumor growth and neovascularization in nude mice, while growth properties of established tumors seem to be independent of FGF-2 expression and vascular density (Giavazzi et al., 2001) .
Tumor progression to the ultimate stages of tumorigenesis, that is, metastasis, results from numerous uncontrolled changes that render tumor cells more motile, invasive and resistant to apoptosis. In this context, survival proteins such as bcl-2 are considered as general antiapoptotic proteins capable of protecting cancer cells from a wide variety of apoptotic stimuli (Chao and Korsmeyer, 1998) . Moreover, in experimental model systems, overexpression of bcl-2 following transfection is associated with lung metastasis (Takaoka et al., 1997; Miyake et al., 1999) .
FGF-2 has been proposed to be a survival and neurotrophic factor for neural precursor cells (Hajihosseini and Dickson, 1999) . The antiapoptotic function ascribed to FGF-2 in PC12 cells has been elucidated with PKC delta implicated in this event, which also requires the Ras/MAPK cascade signaling pathway (Wert and Palfrey, 2000) . The high molecular weight FGF-2 isoform also regulates PKC delta and ERK signaling in pancreatic cells (Gaubert et al., 2001) . Furthermore, in small-cell lung cancer cells, FGF-2 has been demonstrated to inhibit apoptosis via the control of inhibitor of apoptosis proteins (Pardo et al., 2002; Pardo et al., 2003) .
Experimental approaches with animal models have been used to analyse the tumor invasion and metastatic process. Spontaneous metastases, defined as those metastases derived from primary tumors, permit analysis of the full metastatic cascade. The process for experimental metastases obtained after intravenous (i.v.) injection of tumor cells, recapitulating the later steps of hematogenous metastasis, is more efficient, although artificial. Metastases can develop efficiently in the lungs in the immunodeficient experimental nude mouse model.
Tumor cell localization during the first hours following i.v. injection appears to be controversial and seems to be dependent on the nature of the cells. Several studies aimed at understanding this phenomena have taken advantage of fluorescent cells expressing green fluorescent protein (GFP). Since GFP detection is not preserved after cell or tissue fixation, their use is limited to vital observation (Naumov et al., 1999; Al-Mehdi et al., 2000) of ex vivo or thick unfixed sections (Farina et al., 1998) . However, by using this approach, it has recently been demonstrated that the metastatic process per se is highly inefficient and very few of the injected cells that reach the lungs are able to grow as metastases (Luzzi et al., 1998) .
We have previously reported that expression of the nuclear 24 kDa FGF-2 allows NBT-II carcinoma cells to give rise to metastatic foci in the lungs of nude mice that have been subcutaneously (s.c.) injected (Okada-Ban et al., 1999) . In order to elucidate the specific role of nuclear FGF-2 and to determine potential nuclear targets, we have generated cells that conditionally express the 24 kDa FGF-2 with the Tet-Off system, and have studied the metastatic ability of these cells. In addition, we investigated the lung colonizing capacities of the nuclear FGF-2-expressing cells, and studied whether this growth factor could initiate a survival program.
Results

Establishment of cells with doxycycline-repressible expression of the 24 kDa nuclear isoform of FGF-2
In order to substantiate our previous study and to confirm that 24 kDa FGF-2 expression indeed results in lung metastases in vivo, NBT-II rat bladder carcinoma cells were produced that conditionally express 24 kDa FGF-2 and EGFP. The parental NBTII cells do not express FGF-2 or its receptor, FGFR1, making this an ideal system in which to study the effects of nuclear FGF-2 (Okada-Ban et al., 1999) . The conditional expression of 24 kDa FGF-2 by NBT-II Tet-Off 24 kDa FGF-2 clones was tested by decreasing the concentration of doxycycline (200-0 ng/ml). Nuclear 24 kDa FGF-2 expression was evaluated in the presence or absence of doxycycline by Western blot analysis of the corresponding cell extracts. The Tet-Off GF12 clone with regulatable 24 kDa FGF-2 expression was shown to express the highest level of growth factor in the absence of doxycycline ( Figure 1a ) and a very low background of the growth factor with high doxycycline concentrations. The nuclear localization of 24 kDa FGF-2 in the GF12 cells was confirmed by immunofluorescence ( Figure 1b ). There were no significant differences in the growth curves of the GF12 cells, in the presence or absence of doxycycline, compared to parental cells (data not shown). In parallel, the EGFP expression was confirmed by direct fluorescence detection in cells grown on glass coverslips, indicating that in the absence of doxycycline, cells express both the nuclear FGF-2 and GFP.
Confirmation that the 24 kDa nuclear isoform of FGF-2 induces the lung metastases by use of conditional expression in carcinoma cells
The Tet-Off GF12 clone was then used in order to modulate the nuclear FGF-2 expression in tumors. Nude mice were s.c. inoculated with Tet-Off GF12 cells, NBT-II cells expressing the 24 kDa FGF-2 (NLS42 cells), NBT-II parental cells and NBT-II Tet-Off cells transfected with the control vector (OVT cells). For each cell type, one group of mice had their drinking water supplemented with doxycycline. Tumor proliferation was analysed comparatively for each cell type and 7 weeks after injection, the lungs of the animals were carefully analysed for metastatic foci after euthanasia. Results reported in Figure 1c indicate that control cells (NBT-II or OVT) gave rise to tumors that proliferate with similar kinetics in the presence or absence of doxycycline in the drinking water. In contrast, the NBT-II Tet-Off GF12 clone grew faster in the absence of doxycycline than in the presence of the antibiotic, indicating that expression of the 24 kDa FGF-2 enhances the tumor growth properties of the cells. These results are in accordance with the tumor growth properties of the NLS42 clone of NBT-II cells, which constitutively express nuclear 24 kDa FGF-2, with the smaller primary tumors from mice injected with the Tet-Off GF12 cells likely to be due to clonal variation (Okada-Ban et al., 1999) .
Importantly, in addition to tumor growth properties being modified upon 24 kDa FGF-2 synthesis, the tumors obtained with the Tet-Off GF12 cells in the absence of doxycycline gave rise to spontaneous lung metastases (6/7 animals), whereas in mice receiving doxycycline, no metastasis was observed (0/7 animals) after 7 weeks. No macroscopic lung metastases were observed in animals injected with the different control cells in the absence or presence of doxycycline.
NBT-II and NLS42 24 kDa FGF-2-producing cells labeled with the PKH26-GL cell linker have similar growth properties and behave like unlabeled cells both in vitro and in vivo Having confirmed that the lung metastases are due to the expression of the 24 kDa FGF-2 isoform, we wanted to examine the survival of the various NBT-II cells in the lung microenvironment using fluorescently labeled cells. The membrane cell linker PKH26-GL was used to fluorescently label NBT-II and NLS42 cells to facilitate their in vivo detection. As shown in Figure 2 , control NBT-II cells and nuclear FGF-2-producing cells (NLS42), both labeled and unlabeled, have similar growth properties in vitro. These results show that PKH26-GL affects neither the cell viability nor the growth properties of the labeled cells. The doubling time of the cells grown in vitro can be estimated to be approximately 24 h in 10% FBS-containing medium. In vivo NLS42 cells formed tumors more quickly than the NBT-II cells (Okada-Ban et al., 1999) and the labeled cells behaved in a manner similar to that seen with unlabeled tumor cells (data not shown).
These results clearly indicate that cell labeling does not affect the growth properties of the cells in vitro or in vivo, and can be used to detect labeled cells directly in tumors.
Expression of 24 kDa FGF-2 allows a cell survival program to occur in the lungs of the mice and growth of experimental lung tumor foci
We then examined whether each cell type is able to survive in the circulation and reach the lungs. By i.v. injecting nude mice with PKH26-GL fluorescent cells, we induced experimental metastasis, taking advantage of the shorter and more predictable experimental time compared to spontaneous metastasis through s.c. injection, in order to ensure cells remained fluorescent by the time they reached the lungs.
We first demonstrated that from 5 min after i.v. injection of live fluorescent control NBT-II or 24 kDa The presence of fluorescent NBT-II and NLS42 cells within the lungs was determined over the period of the experiment, and results show that during the first 24 h both NBT-II and NLS42 cells were present at a similar level within the lungs (Figure 3b ). However after 48 h, which appears to be a critical time, the NBT-II cell number dramatically decreased. From that time almost all NBT-II cells disappeared, while NLS42 cells proliferated with an approximate in vivo doubling time of 30 h ( Figure 3b : from 48 to 144 h, 3.2 generations).
Analysis of TUNEL labeling showed that apoptosis for the two cell types within the lung was different. During the first 48 h following i.v. injection, some of the NBT-II and NLS42 cells died due to apoptosis; then, NLS42 cells started to proliferate while NBT-II cell apoptosis was maintained (Figure 3c ). Consistent with the levels of apoptosis observed, there was strong immunolabeling for the survival protein bcl-2 detected in the lungs of the animals injected with NLS42 cells, and labeled metastatic foci corresponding to proliferating cells were obvious at day 6 ( Figure 5 ). Conversely, there was little bcl-2 labeling in the lungs of mice injected with parental NBT-II at any time point after injections ( Figure 5 ).
For the two cell types, which show an increasing rate of apoptosis (10% of the total population for NBT-II cells and 7.5% for NLS42 cells), the 48 h post-injection appears to be a critical period. The apoptotic program is maintained for NBT-II cells and almost all the remaining tumor cells within the lungs were apoptotic by day 6 (Figure 3c ). In contrast, apoptosis preceded a survival program in the case of 24 kDa FGF-2-expressing cells (Figure 3c) . This program appears to be essential as soon as day 3 and by day 6 (144 h) NLS42 cell proliferation was obvious with macroscopic foci readily detectable in the lungs of the animals at days 6 and 13.
NLS42 cells, which produce 24 kDa FGF-2, are able to survive in vitro for longer than the parental NBT-II cells Despite the previously described phenotypic differences and distinct in vivo behavior, the NBT-II and 24 kDa FGF-2-producing NLS42 cells behave similarly in a variety of in vitro culture experiments. In particular, there are no significant differences in their growth rates under normal and low serum conditions (data not shown). We also studied the anchorage-independent proliferation of the NBTII and NLS42 cells to determine whether anoikis is involved in the in vivo apoptosis of the NBTII cells. It appears unlikely that anoikis is the apoptotic stimulus in vivo as both cell types survived and proliferated in anchorage-indepen- Nuclear FGF-2 and metastatic survival RJ Thomas-Mudge et al dent proliferation assays, and there were no significant differences in the rate of formation, size or morphology of the cell colonies.
Given the striking in vivo survival difference between the cells, in vitro survival experiments were performed. At 48 h after plating the cells in media with 10% FBS, the media were replaced with serum-free media and the cells cultured for a further 4 days. The results reveal that the NLS42 cells are able to survive for longer in the absence of serum than the NBT-II cells (Figure 6a ). TUNEL assays were performed on the cells over the time course of serum starvation to determine the level of There was a significant difference between the number of NBT-II and NLS42 cells that were apoptotic at days 3 and 4 (*Po0.02 and **Po0.01) Nuclear FGF-2 and metastatic survival RJ Thomas-Mudge et al apoptosis, which revealed that there is an increase in the number of apoptotic NBT-II cells compared to the NLS42 cells (Figure 6b and c) , which was significant at days 3 and 4 (Figure 6c , *Po0.02 and **Po0.01).
Discussion
Evidence indicates that some of the activities of FGF-2 may depend on an intracrine mode of action depending on putative 24 kDa FGF-2 nuclear targets (Van den Berghe et al., 2000; Sun et al., 2001) . It has been shown that within the nucleus, high molecular weight FGF-2 interacts directly with and induces chromatin compaction in cardiac myocytes, independent of apoptosis or mitosis, but it may also contribute to the regulation of specific gene expression (Karsan et al., 1997) . FGF-2 has been reported to act as an antiapoptotic factor (Funato et al., 1997; Pardo et al., 2002; Pardo et al., 2003) . However, in other systems, it has been reported that FGF-2 could induce apoptosis (Maloof et al., 1999) .
The use of cells expressing doxycycline-regulatable FGF-2 expression is a powerful tool, and it has been reported that expression in NIH-3T3 cells of high molecular weight FGF-2 allowed cell growth in low serum, while expression of 18 kDa FGF-2 did not (Gualandris et al., 1999) . Specific expression of the nuclear 24 kDa FGF-2 with the Tet-Off system in the carcinoma NBT-II system was utilized to show that metastatic behavior is a direct consequence of 24 kDa FGF-2 expression in the nucleus. NBT-II cells producing nuclear FGF-2 in the absence of doxycycline have an increased tumorigenicity and most importantly give rise to lung metastases, thereby mimicking the behavior of the 24 kDa FGF-2-expressing NLS42 cells which were used for the remaining studies.
Spontaneous metastases were only detected in the lungs of the NLS42 tumor-bearing animals at the time of euthanasia. Despite extensive investigations, neither macrometastases (visible at autopsy) nor micrometastases (revealed after in vitro culture of the selected dissociated organ) were detected in organs other than the lungs or lymph nodes. This could represent the limit of the immunodeficient mouse model or a particular propensity of the bladder cancer cells to target and establish in the lung, so that this model provides a physiologically relevant setting to dissect the process of metastasis.
The detection of hematogenous metastasis could be performed after induction of experimental metastasis following i.v. injection of tumor cells. In this case, the lung is the first major organ to be encountered by the cells and those competent for metastasis, having bypassed the extravasation steps of the metastatic process, will intravasate, proliferate and establish if the organ microenvironment is suitable.
Fluorescent tumor and metastases imaging analysis is a robust system that allows tumor cell detection both in vivo and in sections. As successfully reported by others (Koop et al., 1995; Naumov et al., 1999; Al-Mehdi et al.,
2000)
, we first used GFP fluorescent cells to detect fluorescent metastatic foci. GFP-NBT-II cells in the lungs of the animals were easily detected by fluorescent microscopy of the entire lungs or thick lung sections observed directly with no fixation, but the injected cells were not homogeneously producing the GFP. The detection of GFP-positive cells or micrometastases on thin unfixed or fixed lung cryosections was unsuccessful as these cells loose their fluorescence. However, the use of GFP-tagged cells was very efficient in monitoring the metastatic process by intravital video microscopy (Naumov et al., 1999) and direct epifluorescence microscopy in intact perfused mouse and rat lung of GFP cell-injected animals was also performed (AlMehdi et al., 2000) . Fluorescent labeling of murine melanoma cells with fluorescent nanospheres allowed the successful monitoring of the cell survival within the lungs of injected animals (Luzzi et al., 1998) .
The use of the vital PKH26-GL cell linker was very effective in our in vivo experiments, as the half-life of the compound is greater than 100 days. We have shown that carcinoma cells are very rapidly extravasated following i.v. injection; NLS42 cells as well as their NBT-II counterparts that reached the lung could be detected outside the vessels 5 min after injection. As soon as 24 h postinjection, the vast majority of the cells that were present within the lungs had extravasated through the endothelium. These results are in agreement with studies performed with melanoma cells (Cameron et al., 2000; Bold et al., 2001) . Since the tumor cell proliferation starts after approximately 48 h, it seems obvious that there is no tumor cell proliferation within the vessel in the NBT-II carcinoma system, which differs from previous data reported for transformed fibroblasts and fibrosarcoma, which give rise to intravascular metastasis (Al-Mehdi et al., 2000) .
Bcl-2 could be a major determinant for the metastatic cell behavior. The level of bcl-2 expression is correlated with the metastatic potential in tumor pancreatic cell lines (Bold et al., 2001) . The MIA PaCa-2 cells overexpressing bcl-2 after stable transfection led to an increase of metastatic incidence in a xenograft system. Similarly, overexpression of bcl-2 enhances the metastatic potential of human bladder cancer cells in the lung of the nude mice that have been i.v. injected (Miyake et al., 1999) ; pulmonary metastasis of B16 melanoma cells were also promoted when cells expressing either bcl-2 or BAG-1 were introduced into the animals (Takaoka et al., 1997) .
Our work clearly demonstrates that apoptosis in vivo, as shown for NBT-II cells, prevents growth of metastatic foci, while induction of a survival program by nuclear FGF-2 expression in vivo that is potentially induced through bcl-2 correlates with growth of the lung metastases. FGF-2 has also been shown to upregulate bcl-2 expression in prostate cancer cells (Rosini et al., 2002) , chronic lymphocytic leukemia cells (Konig et al., 1997) and NIH-3T3 cells (Wieder et al., 1997) , resulting in the prevention of apoptosis. Conversely, it has been reported that downregulation of bcl-2 mediated by FGF-2 expression in human breast cancer cell lines promotes apoptosis (Maloof et al., 1999) . Wong et al. (2001) have reported that when using metastatic transformed rat embryo fibroblasts, apoptosis in the lung is an important component of the metastatic inefficiency; however, when these cells overexpressed bcl-2, apoptosis was inhibited and growth of metastatic foci was readily detectable in the lung of i.v. injected animals.
Interestingly, significant apoptosis precedes the survival program in NBT-II carcinoma cells producing nuclear FGF-2; this may be due to transiently inadequate cell-cell or cell-matrix interactions in the lung microenvironment or could reflect the delay in setting up a 24 kDa FGF-2-stimulated survival program within this environment. It seems unlikely that anoikis is the apoptotic stimulus in vivo as both NBTII and NLS42 cells were able to proliferate and form colonies in anchorage-independent proliferation assays. Not only can the 24 kDa FGF-2-producing cells metastasize and proliferate within the lung in response to an antiapoptotic program, but we cannot exclude that these cells are also able to proliferate in response to a suitable microenvironment in the surrounding lung tissue.
We have also demonstrated that the nuclear FGF-2-producing NLS42 cells have an enhanced ability to survive in vitro compared to the NBT-II cells after serum deprivation. However, in vitro studies have not yet established the mechanism by which 24 kDa FGF-2 confers a survival advantage upon the NLS42 cells. Differential expression of antiapoptotic proteins such as phosphorylated Akt has not been detected between NBTII and NLS42 cells in vitro under either normal or stressed conditions (data not shown). Clearly, the elucidation of the mechanism through which nuclear FGF-2 is able to promote cell survival is vital and work is underway to discover proteins that interact with FGF-2 in the nucleus and potential downstream targets.
It is hoped that the identification of the pathways through which nuclear FGF-2 induces or modifies the metastatic phenotype in animal models will contribute to the development of strategies for the treatment of human cancer metastases. Particularly in light of recent evidence that the expression of nuclear FGF-2 is correlated with a poor prognosis and increased metastasis in some human cancers.
Materials and methods
Cells
The NBT-II cell line is derived from a chemically induced rat bladder carcinoma (Toyoshima et al., 1971) . These epithelial cells do not produce FGF-2 but express the FGFR2b splice variant of the FGFR2 receptor (Savagner et al., 1994) .
Transfected NBT-II cells expressing the 24 kDa FGF-2 nuclear isoform (NLS42 cells) have been reported previously (Okada-Ban et al., 1999) .
Conditional 24 kDa FGF-2 expression with the Tet-Off system
A 640 bp Xba1-HindIII fragment from the pRFEneo vector containing the complete sequence for the human 24 kDa FGF-2 (Okada-Ban et al., 1999) was cloned into the bidirectional plasmid pBI-EGFP (Clontech) to create the pBI-EGFP/ 24 kDa FGF-2 mammalian expression vector. This construct allows the expression of both EGFP and 24 kDa FGF-2 in the absence of doxycycline.
The NBT-II Tet-Off cell line expressing the tTA regulator was a kind gift from Dr Bonneton (unpublished), which was established by transfecting the NBT-II cells with a plasmid derived from the original pUHD15-1 p-Tet-Off vector (Gossen and Bujard, 1992) and containing the resistance gene for puromycin as a selective marker (NBT-II-Tet-Off clone B8). These cells were further cotransfected with the recombinant pBI-EGFP/24 kDa FGF-2 and a plasmid coding for the Neo R selective marker. Clones were then selected in 400 mg/ml G418-containing medium.
Clones expressing nuclear FGF-2 in the absence of doxycycline were used for further experiments; they differ in both their growth factor expression level and morphology (i.e. epithelial, like parental cells or fibroblastoid). The extinction of the 24 kDa FGF-2 expression was tested by growing cells in increasing concentrations of doxycycline from 50 to 200 ng/ml. These cells were also used for in vivo experiments, and the inoculated mice were either treated or not treated with doxycycline added to their drinking water (2 mg/ml with 5% sucrose).
Immunoblot analysis
Samples were boiled for 5 min in Laemmli buffer containing 5% b-mercaptoethanol and 2% SDS. Proteins were separated by electrophoresis in a 10% SDS-PAGE ready gel (Biorad) and were transferred electrophoretically overnight onto polyvinylidene fluoride membrane (Immobilon-P, Millipore) in 50 mM Tris, 50 mM glycine. The membrane was then saturated by incubation for 1 h with 3% BSA in 20 mM Tris-HCl pH 7.5, 137 mM NaCl, 0.01% Tween-20 and incubated for 1 h at room temperature with the specific antibody. The anti-FGF-2 antibody used for Western blot analysis was a polyclonal antibody (Chemicon). The membrane was incubated with the secondary antibody and treated with enhanced chemoluminescence reagent (ECL, Amersham). Prestained molecular mass markers (Biorad) were run on each gel.
Tumor induction and spontaneous metastases in nude mice
NBT-II cells or 24 kDa FGF-2-producing cells (3.5 Â 10 6 cells) were injected s.c. into the flank of 6-week-old female Swiss nude mice (nu/nu, Iffa Credo, Les Oncins, France). Five animals were used per experiment. Their care and housing were in accordance with the guidelines from the French Ethical Committee (Ministe`re de l'Agriculture). When the tumor volume reached approximately 2000 mm 3 , tumors and lungs were aseptically removed; part was trypsinized and maintained in culture in vitro, some fragments were placed directly into OCT embedding medium (Tissue-Tek), some was frozen in liquid nitrogen-cooled isopentane, cryosectioned and stored at À801C for further analysis, and/or part was treated with Bouin fixative solution for anatomopathological direct observation.
Vital cell labeling
Membranes of living cells were labeled with the PKH26-GL red fluorescent cell linker according to the manufacturer (Sigma/Biosciences). This fluorescent linker binds the cell membrane. Trypsinized cells (2-5 Â 10 6 ) were washed with phosphate-buffered saline (PBS) and resuspended in 0.5 ml of the manufacturer diluent C; 2 ml of PKH26-GL dye was diluted to 500 ml with diluent C and added to the cell suspension at room temperature for 5 min with gentle shaking. The reaction was stopped with 1 ml of fetal bovine serum. After three washes in complete medium, labeled cells were resuspended and counted. Cell plating efficiency was then performed to evaluate the cell viability after labeling. To show that the labeling did not alter the cell growth properties, labeled and unlabelled NBT-II and NLS42 cells were seeded in 3.5 cm diameter dishes at 25 000, 50 000 and 100 000 cells/dish in complete medium and counted after 48 h.
i.v. Injection of tumor cells and experimental metastases
Single-cell suspensions (1.75 Â 10 6 cells in 0.1 ml of PBS) of freshly prepared PKH26-GL rhodamine fluorescent NBT-II or NLS42 cells were i.v. injected into each animal; for practical reasons and reproducibility, mice were injected in the ocular sinus. Three different series of experiments were performed using an identical experimental procedure.
Injected animals were killed at 5 min, 2 h, 24 h, 48 h, 6 days and 13 days after injection and the lungs were aseptically removed; careful autopsy of each animal was performed to detect macrometastases in other organs. After longer periods of time, the survival of NLS42-injected mice is greatly endangered due to impaired breathing, and animals were therefore killed at 2 weeks.
Ex vivo observation and processing of the lungs
Preliminary experiments have shown that the cell distribution between the right and left lungs from i.v. injected mice are similar. Freshly dissected right lungs were directly observed at Â 50 under a fluorescent microscope and then rapidly frozen in isopentane after embedding (Tissue Teck), and stored at À801C. Serial cryosections (6 mm) were performed for further observation and specific labeling.
After removal, left lungs were immediately injected with buffered formaldehyde to preserve the morphology and embedded in paraffin for later sectioning. Lungs of the injected animals that were killed at day 13 were first observed for their fluorescence, then fixed in Bouin and directly analysed for their morphology and presence of metastatic foci with a Leica MZ8 dissection microscope coupled to a JVC CDD camera. Image acquisition was carried out with the Scion Image 1.62a software.
Microscopic observation of the tumor cells within the lungs
Lung cryosections were analysed for the presence of PKH26-GL fluorescent cells. Since the fluorescence is not resistant to cell fixation, air-dried sections were directly mounted with cyanocrylate (Superglue s ), which preserves fluorescence and observed under a Leica DMRBE microscope ( Â 200) coupled to a CCD Hamamatsu camera. To allow comparison between the different sections, images were acquired with identical parameters for all the acquisitions (Photoshop s software; magnification: Â 200; exposure: 0.4 s; gain: 8)
Paraffin sections were used for HES (hematein/eosin/safran) staining and labeling with specific antibodies. The sections were observed at Â 25, Â 400 and Â 1000 under a Leica DMRB microscope coupled to a CDD camera and acquired with Claravision s software.
Immunofluorescence analysis
The anti-FGF-2 antibody used for immunofluorescence detection was a polyclonal antibody (Chemicon). Anti-bcl-2 was a rabbit polyclonal antibody (Santa Cruz Biotechnology). Cells were grown on thin glass coverslips for 1-3 days before experiments and fixed in 4% paraformaldehyde in PBS. Fixed cells were permeabilized with PBS containing 0.1% Triton X-100 for 20 min at room temperature, followed by washing and blocking with 5% normal serum in PBS. Cells or sections were incubated with PBS-diluted FGF-2 antibody (1 : 25) overnight at 41C and after washing, stained with fluorescently labeled secondary antibody for 1 h at room temperature. Apoptotic cells in cultured cells and in lung sections were localized by TUNEL assay with the Apoptag s labeling kit (Quantum Appligen) using a rhodamine-coupled antidigoxigenin antibody according to the supplier's protocol. Nuclei were counterstained with DAPI. Cryosections fixed for Apoptag s labeling resulted in the complete disappearance of the fluorescent PKH26-GL signal; thus, red fluorescence only results from Apoptag s labeling in the computer-analysed sections.
Computer analysis: percentage of apoptotic cells PKH26-GL red fluorescence of tumor cells within the lung sections and fluorescence signal for apoptosis (Apoptag s positive cells) are not comparable on the same section. We thus determined the cell number corresponding to each fluorescent signal from two serial sections (one for total fluorescent cell number and the other for the Apoptag s signal) for each experimental condition. Fluorescence of five randomly chosen fields for each section was determined for each condition and the total fluorescence expressed as total pixels was determined: total fluo pixels PKH26-GL ¼ F-PKH and total fluo pixels Apoptag ¼ F-APO.
The fluorescence intensity for each cell type and fluorescent label (NBT-II-PKH26-GL, NLS42-PKH26-GL, NBT-II-rhodamine-Apoptag and NLS42-rhodamine-Apoptag) was determined using NIH software on 20-30 cells. The mean fluorescence for one cell in each case was thus determined in pixels: one cell fluo pixels PKH26-GL ¼ f-PKH and one cell fluo pixels Apoptag ¼ f-APO.
The percentage of apoptotic tumor cells within the lungs was determined for each experimental condition from the ratios (F-PKH)/(f-PKH) ¼ number of PKH26-GL cells in five fields and (F-APO)/(f-APO) ¼ number of apoptotic cells in five corresponding fields.
Anchorage-independent proliferation assay
Anchorage-independent proliferation assays (growth in soft agar) were performed in six-well plates. The plates were coated with 1.5 ml of 0.5% DNA grade agarose in DMEM þ 10% FBS. Agarose (1%) was melted in dH 2 O, allowed to cool and mixed with an equal volume of 2 Â DMEM þ 20% FBS. The agarose was set at 41C for 30 min and equilibrated to room temperature before use. Cells were trypsinized and 2 Â 10 5 cells (0.1 ml of 2 Â 10 6 cells/ml) were mixed with 3 ml 0.7% molten agarose (at 371C) and 3 ml 2 Â DMEM þ 20% FBS. Cell mixture (1.5 ml) was then plated onto the bottom layer of agar and the cells cultured for 10 days. When numerous colonies were visible, the plates were stained with 0.5 ml of 0.005% crystal violet solution for 1 h. Wells were photographed and the colonies counted.
In vitro survival assay NTBII and NLS42 cells were trypsinized and seeded at 50 000 cells/well on glass coverslips in six-well plates and allowed to grow for 48 h. The media were then replaced with the serumfree media (day 0) and the cells cultured for a further 4 days. Cells were imaged each day with a Nikon MR series microscope ( Â 20) with a CCD camera. Coverslips were fixed in 4% PFA at each time point and Apoptag s labeling and DAPI counterstaining performed at the completion of the experiment. The total number of cells and the number of apoptotic cells in at least five fields per time point were counted to determine the percentage of cells that were apoptotic for each cell type with standard error of the mean shown at each time point (*Po0.02 and **Po0.01). The results are representative of two independent experiments.
